

PCTWORLD INTELLECTUAL
PROPERTY ORGANIZATION

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 9603657A1

(51) International Patent Classification ⁶ : G01N 33/68, 33/72		A1	(11) International Publication Number: WO 96/03657
			(43) International Publication Date: 8 February 1996 (08.02.96)
(21) International Application Number: PCT/GB95/01766		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 26 July 1995 (26.07.95)			
(30) Priority Data: 9415143.8 27 July 1994 (27.07.94) GB			
(71)(72) Applicants and Inventors: EDWARDS, Raymond [GB/GB]; 8 The Elms, Vine Road, London SW13 0NF (GB). BLINCKO, Stuart, James, Frederick, Edward [GB/GB]; 124 Selmeiston Road, Eastbourne, East Sussex BN21 2TL (GB).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(74) Agent: RAYNOR, John; W.H. Beck, Greener & Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).			
(54) Title: GLYCATED PROTEINS ASSAY			
(57) Abstract <p>A solution phase assay of glycated proteins, such as glycated haemoglobin and plasma-soluble glycated proteins, is carried out by reacting the assay sample with a photoluminescent or chemiluminescent marker compound containing a boronic acid group which reacts selectively with the glycated protein. The luminescence of the marker compound is excited at a wavelength at which it is preferentially quenched by the binding of the marker compound to the glycated protein. The quenching in luminescence gives a measure of the degree of glycation of the glycated proteins.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

GLYCATED PROTEINS ASSAY

5 This invention relates to a method for carrying out an assay for glycated proteins, such as glycated haemoglobin.

10 The level of glycated haemoglobin in blood is a quantity which is used routinely to assess diabetic patients. High levels of circulating glucose lead to high percentages of glycated proteins. For example, in a non-diabetic person, the percentage of haemoglobin molecules that have been glycated (i.e. to which glucose has bound non-enzymatically) is 4.5 - 8.0 percent. In a diabetic patient, the levels are much higher (unless treatment is given) and can in severe cases be as much as 20 percent. 15 The level of glycated haemoglobin can therefore be used to monitor treatment.

20 Virtually all existing methods for the determination of glycated haemoglobin in blood samples depend upon the separation of glycated haemoglobin using for example chromatography, electrophoresis, or solid phase reagents with washing step, prior to measurement.

25 For example, Wilson et al. (Clin Chem 39/10, 2090-2097 (1993)) describe an assay method for glycated haemoglobin in which the glycated haemoglobin is labelled with a soluble polyanionic affinity reagent, and the anionic complex is then captured with a cationic solid-phase matrix. In this method, the amount of glycated haemoglobin 30 bound to the solid phase matrix is then determined by measuring the quenching by the haemoglobin of the static fluorescence from an added fluorophore.

35 EP-A-455225 (Nacalai Tesque, Inc.) discloses a method for determining the percentage of glycation of a particular

-2-

protein. First, the protein is separated from the sample which contains it by preferentially binding it to an antibody which is fixed to a solid support. The support is then washed with labelled boronic acid, which binds to the glycosylated site on the protein. The liquid and solid phases are separated, and the amount of boronic acid bound to the protein in the solid phase can be measured, thereby allowing the number of glycosylated protein molecules to be calculated.

10

US-A-4861728 (Becton, Dickinson & Co) describes a method of determining the percentage of glycosylated haemoglobin in blood. In this method, the total haemoglobin is separated from the liquid phase by binding it to a dipstick, and then the glycosylated haemoglobin is reacted with a dihydroxyboryl reagent conjugated to a fluorescent dye. The absorption of incident light by the dye provides a measure of the amount of glycosylated haemoglobin. This can be compared with the total amount of haemoglobin, which can be calculated by measuring the absorption of incident light at the absorption wavelength for haemoglobin.

A similar method is described in WO 90/13818 (Axis Research AS). In this method, the glycosylated haemoglobin-containing sample may be haemolysed to liberate any cell bound haemoglobin. Signal-forming molecules conjugated to dihydroxyboryl residues are then reacted preferentially with the glycosylated haemoglobin, the total haemoglobin is separated from the sample, and the amount of glycosylated haemoglobin is measured by measuring the amount of signal-forming molecules.

WO93/18407 (Abbot Laboratories) is concerned with a method of measuring the amount of glycosylated haemoglobin in a sample, by reacting the total haemoglobin with a

-3-

fluorescent marker, and measuring the fluorescent quenching due to the total haemoglobin. The glycated haemoglobin is then separated from the sample by standard methods (ion capture or solid phase separation), and the fluorescent
5 quenching due to it is measured. The two quenching measurements give a percentage of the total haemoglobin which is glycated. The specific binding agent for glycated haemoglobin which is employed is coupled to a latex
10 particle or to polyacrylic acid, in order to achieve the separation of glycated and non-glycated haemoglobin which is essential to the operation of the method.

Separation assays of this kind are time consuming and thus expensive to carry out in practice.
15

A non-separation assay for glycated albumin is described by Yukiko Hayashi et al. (Clinica Chimica Acta, 149 (1985) 13-19).

20 The method relies on a specific reaction between the particular fluorophore employed (dansylated phenyl boronic acid) and glycated albumin, which results in the enhancement of the fluorescence of the dansylated phenyl boronic acid. The reason for the enhancement is not
25 explained by the authors, but it clear from the paper that the phenomenon is albumin-specific, i.e., it relies on the specific interaction between albumin and the particular fluorophore employed.

30 Albumin in blood has a relatively short lifetime, and therefore it is not particularly suitable as an marker for levels of glycation.

Also, because of the nature of the particular
35 fluorophore employed (dansylated phenyl boronic acid), excitation of the fluorophore to produce fluorescence must

-4-

take place in a region of the spectrum in which proteins also absorb strongly (around 350nm). This results in a disadvantageously high background signal against which fluorescence enhancement must be measured.

5

No liquid phase (i.e., non-separation) assay is available for glycated proteins other than albumin.

10 We have now found that it is possible to carry out a solution phase assay of glycated proteins other than albumin, such as glycated haemoglobin and plasma-soluble glycated proteins, by reacting an assay sample containing the said glycated protein with a photoluminescent or chemiluminescent marker compound (such as a fluorescent
15 compound containing a fluorescein residue), containing a boronic acid group capable of binding with the cis-diol group of the glycated protein, which marker compound is not albumin-specific. The luminescence (typically, fluorescence) of the said residue is then detected at a
20 wavelength such that luminescence is preferentially quenched by the bound glycated protein (e.g., glycated haemoglobin), to an extent which depends upon on the amount of glycated protein which is present (more specifically, on the degree of glycation of the protein present). The
25 amount of the protein present in the solution can thus be determined by the change in luminescence (e.g. fluorescence) caused by such quenching.

Accordingly, in the first aspect of the invention,
30 there is provided a method of carrying out an assay for a glycated protein in a sample, which method comprises carrying out a reaction in solution between an assay sample and photoluminescent or chemiluminescent marker compound containing a boronic acid group capable of
35 selective binding with the cis-diol group of a glycated protein, which marker compound is not albumin-specific,

-5-

exciting the luminescence in the marker compound, and detecting the resulting luminescence,

wherein the nature of the marker and the nature of the excitation are such that the said luminescence occurs at a wavelength at which it is preferentially quenched by the binding of the said marker compound to the said glycated protein, and

determining the quenching in luminescence due to the binding of the said marker compound to the glycated protein.

The term "photoluminescent" as used herein is intended to include both phosphorescence and fluorescence, although it is preferred that the photoluminescent compound is a fluorescent compound. It is preferred that the fluorophore has a principal excitation wavelength of from 450 to 800nm, (ie. somewhat distant from the principal excitation wavelength of proteins). It is further preferred that the principal fluorescence wavelength is from 450 to 600nm.

It is particularly preferred that the marker compound contains the residue of a fluorescent compound such as fluorescein or a fluorescein derivative, for example carboxyfluorescein or a chlorofluorescein. In this case, the excitation wavelength is preferably approximately 480nm, and the fluorescence is preferably detected at approximately 520nm.

Other complex organic molecules which are chemiluminescent or phosphorescent rather than fluorescent can also be used as luminescent markers in the method of the invention, provided that their chemiluminescence or phosphorescence can be selectively quenched by covalent bonding to a glycated protein such as glycated haemoglobin.

35

-6-

Other suitable fluorophores are the following (the figures shown in parentheses are the principal excitation and fluorescence wavelengths)

- 5 naphthofluorescein (λ_{ex} 600nm λ_{em} 672nm)
 eosin (λ_{ex} 522nm λ_{em} 543nm)
 erythrosin (λ_{ex} 528nm λ_{em} 553nm)
 coumarin and umbelliferone (λ_{ex} 360nm λ_{em} 460nm)
 derivatives
- 10 rhodamine derivatives
 e.g. Rhodamine B (λ_{ex} 550nm λ_{em} 585nm)
 tetramethyl rhodamine (λ_{ex} 540nm λ_{em} 570nm)
- 15 texas red derivatives (λ_{ex} 589nm λ_{em} 615nm)
 lucifer yellow derivatives (λ_{ex} 420nm λ_{em} 535nm)
 Various BODIPY (4,4-difluoro-4-bora-3a,4a diaza-s-indacine) derivatives
- 20 NBD-halide (4-halogeno-7-nitrobenzo-2-oxa-1,3-diazole) derivatives
 Lanthanide chelate derivatives
 Transition metal chelate derivative, e.g. Ru tris phenanthroline or Ru tris bipyridyl derivatives
- 25 Phycobiliprotein derivatives

 The group capable of selective binding with a cis-diol is a boronic acid group. Boronic acids are known to form
30 covalent (but not particularly stable) bonds with the cis-diol groups of glycosylated proteins. The bonds formed are, however, sufficiently stable to enable the assay determination to be made in solution.


35

- 7 -

Haemoglobin is a known quencher of fluorescence. If a fluorescent molecule is bound covalently and specifically to glycated haemoglobin, but not to non-glycated haemoglobin molecules, it is possible to derive, without separation, a measure of the level of haemoglobin glycation directly from the measured amount of fluorescence quenching. High levels of glycated haemoglobin will quench the fluorescent signal more than low levels. The same effect is observed with other glycated proteins, for example, plasma-soluble or serum-soluble glycated proteins.

The principal application of the assay method of the invention is in the measurement of glycation levels of blood proteins linked to the control of diabetes.

The preparation of boronic acid derivatives of fluorescein is described for example, in DE-A-3720736. The derivative employed in the present invention is preferably a compound of the formula $F-A-B(OH)_2$, wherein F is a fluorescein residue, and A is a suitable linking group to link the fluorescein residue to the boronic acid group. In a preferred embodiment, the linking group A may be a group of the formula $-NH.CS.NH.Ph-$, wherein Ph is a phenyl group. In a particular preferred embodiment, the compound has the formula:-



- 8 -

A number of preferred embodiments of the invention are described in the following Examples.

The following buffers were employed in the Examples:-

5

Carbonate Buffer

4.2 ml of sodium hydrogen carbonate was dissolved in
10 500ml distilled water and the pH adjusted to 9.0 by
addition of solid sodium carbonate.

Assay buffer

15 7.51g glycine and 10.16g magnesium chloride hexahydrate
were dissolved in 1000ml distilled water. The pH of the
solution was adjusted to 8.5 by addition of 1.0M sodium
hydroxide solution.

20 Sample lysing buffer

2ml of a lysing detergent (TM TRITON X-100) was
dissolved in 100ml of assay buffer.

25

Example 1

A fluorescein-boronic acid compound of formula I above
was prepared by the following method. Fluorescein
isothiocyanate (10mg), m-aminophenylboronic acid (4mg) and
30 triethylamine (3mg) were mixed in 0.9ml methanol, and 0.1ml
distilled water. The mixture was stirred for one hour at
room temperature and then a further 4mg of m-aminophenyl-
boronic acid was added. Stirring was continued for a
further hour, and the solution was then purified by thin
35 layer chromatography (eluent dichloromethane : methanol,
9:1).

-9-

The green band (R_f 0.2-0.3) was eluted from the silica with methanol, and the resultant solution stored at -20°C . 0.5ml of the methanol solution was diluted in 4.5ml carbonate buffer and the optical density recorded at 492nm. It was established that the optical density was proportional to the concentration, the optical density being $8.78 \times 10^4 \times$ the concentration in mols/litre.

The solution was diluted in the assay buffer to a concentration of 5nmols/l.

Example 2 - Glycated Haemoglobin Assay

Whole blood samples were collected from patients and stored at 4°C with an EDTA anti-coagulant.

The samples were centrifuged at 3000rpm for 5 minutes. 50 μ l aliquots were added to 450 μ l sample lysing buffer and vortex mixed.

20 μ l aliquots of the lysate were added to 2ml samples of the fluorescent tracer solution prepared in Example 1, vortex mixed, and left in the dark for 30 minutes at room temperature. The samples were then read on a fluorimeter (Perkin Elmer LS20™ equipped with a flow cell), at 520nm (excitation frequency 480 nm). Similar runs were made without sample addition as controls and the total quenching for each of the sample runs was determined by difference.

Total haemoglobin content of each of the measured samples was also quantified by UV spectrophotometry using a CECIL 300™ UV instrument at 405 nm, and the ratio calculated of the level of fluorescence quenching to the total haemoglobin content (as measured by $\Delta F/\text{OD}$, where ΔF is the decrease in signal measured at 520nm caused by

-10-

quenching, and OD is the optical density measured at 405nm).

5 The glycated haemoglobin level (%HbA1) of the same blood samples was measured using a commercially available test kit (Corning), and the results are tabulated in Table I. Figures 1 and 2 respectively show graphically the correlation between ΔF , and %HbA1, and between $\Delta F/OD$, and %HbA1. The clear correlation in Figure 2 demonstrates that
10 the single phase fluorescence quenching method of the present invention may be used as an accurate measure of glycated haemoglobin level of a blood sample. The correlation in Figure 1 illustrates that ΔF alone may in some circumstances (namely, when the total haemoglobin
15 level is known not to differ widely between samples) be a sufficiently accurate measure of HbA1 content.

Example 3 - Plasma Assay

20 Whole blood samples were collected from patients as in Example 2 and stored at 4°C with an EDTA anti-coagulant.

The samples were centrifuged at 3000rpm for 5 minutes. 50 μ l aliquots of the supernatant plasma was diluted to
25 500 μ l with 450 the same buffer as used in Example 2, and vortex mixed.

20 μ l aliquots of the mixed solution were added to 2ml samples of solution prepared as in Example 1, vortex mixed,
30 and left in the dark for 30 minutes at room temperature. The samples were then read as in Example 2.

The glycated haemoglobin level of the original blood samples was again measured using the Corning test kit. The
35 results are tabulated in Table 2. The same results are shown graphically in Fig. 3.

-11-

In this case, fluorescence quenching is not caused directly by glycated haemoglobin, since the level of glycated haemoglobin in the plasma sample is negligible. The quenching is clearly caused by the presence in the plasma of some other glycated protein. Table 2 and Figure 3 clearly illustrate that a strong correlation also exists between the glycated haemoglobin level in the original blood samples and fluorescence quenching caused by the presence of this material in the supernatant plasma. For clinical purposes, it is not necessary to know the precise nature of glycated plasma protein which causes the fluorescence quenching, provided that the amount of fluorescence quenching correlates with the level of glycated haemoglobin level in the original blood samples.

EXAMPLE 4 - Whole blood

Whole blood samples were collected from patients and stored at 4°C with an EDTA anti-coagulant.

The samples were rotated for 10 minutes. 50 µl aliquots were added to 450 µl sample lysing buffer and vortex mixed. These were left at room temperature for 1 hr.

20 µl aliquots of the lysate were added to 2 ml of the fluorescent tracer solution as prepared in Example 1, vortex mixed, and left in the dark for 30 minutes at room temperature. The samples were then read on a fluorimeter (Perkin Elmer LS20™ equipped with a flow cell), at 520 nm (excitation frequency 480 nm). Similar runs were made without sample addition as controls and the total quenching for each of the sample runs was determined by difference.

The glycated haemoglobin level (%HbA1c) of the same blood samples was measured using a commercially available

-12-

Table 3. Figure 4 shows graphically the correlation between ΔF and %HbA1c. The correlation shown in Figure 4 demonstrates that the single phase fluorescence quenching method of the present invention may be used as an accurate measure of glycation level of a blood sample.

EXAMPLE 5 - Filter paper blood spot

30 μ l samples were collected from patients, spotted onto absorbent filter paper and stored at room temperature.

Filter paper blood spots, cut using a hole-punch, were added to 2 ml of the fluorescent tracer solution as prepared in Example 1, vortex mixed and left in the dark for 60 minutes at room temperature. The samples were then vortex mixed and read on a fluorimeter (Perkin Elmer LS20TM equipped with a flow cell), at 520 nm (excitation frequency 480 nm). Similar runs were made without sample addition as controls and the total quenching for each of the sample runs was determined by difference.

The glycated haemoglobin level (%HbA1c) of the same blood samples was measured using a commercially available test kit (HPLC method) and the results are tabulated in Table 4. Figure 5 shows graphically the correlation between ΔF and %HbA1c. The correlation in Figure 5 demonstrates that the single phase fluorescence quenching method of the present invention may be used as an accurate measure of glycation level of a blood spot sample.

EXAMPLE 6 - Use of other fluorophores

An umbelliferone-boronic acid compound was prepared by the following method.

-13-

7-hydroxy-4-methylcoumarin-3-acetic acid succinimidyl ester (10 mg) in dimethylformamide (100 μ l), and m-aminophenylboronic acid (5 mg) in pH 9.0 carbonate buffer (100 μ l) were mixed and stirred for 1 hour in the dark.

5 The solution was purified by thin layer chromatography (eluent chloroform: methanol, 4:1).

A band (R_f 0.79-0.82) was eluted from the silica with methanol. An aliquot of the methanol solution was diluted

10 tenfold in carbonate buffer pH 9.0. The concentration of product was calculated using the optical density at 360 nm and an extinction coefficient of 17,000.

The quenching of the prepared umbelliferone-boronic

15 acid derivative was measured using the procedure given in Example 3, but with 100 nM concentration of the umbelliferone-boronic acid derivative and 200 μ l aliquots of samples diluted tenfold. The results are shown in Table 5

20

It will of course be understood that the invention may be put into practice in many other ways in addition to those specifically outlined above. In particular, the nature of the fluorophore may be varied, appropriate

25 changes being made to the excitation frequency.

-14-

Table 1

Sample	Meas. (F) ³	ΔF	Hb OD	Ratio	Corning ¹
1	724.50	94.30	0.380	248.16	4.80
1	728.20	90.60	0.380	238.42	4.80
2	719.30	99.50	0.359	277.16	5.50
2	721.40	97.40	0.359	271.31	5.50
3	727.80	91.00	0.380	239.47	7.60
3	726.80	92.00	0.380	242.11	7.60
4	711.70	107.10	0.396	270.45	8.90
4	715.20	103.60	0.396	261.62	8.90
5	696.50	122.30	0.378	323.54	11.20
5	698.70	120.10	0.378	317.72	11.20
6 ²	701.60	117.20	0.376	311.70	11.60
6 ²	700.50	118.30	0.376	314.63	11.60
7	691.60	127.20	0.382	332.98	12.20
7	691.30	127.50	0.382	333.77	12.20
8	682.00	136.80	0.403	339.45	15.10
8	683.20	135.60	0.403	336.48	15.10
9	658.70	160.10	0.391	409.46	16.70
9	661.20	157.60	0.391	403.07	16.70

1.results of Corning test are given as %HbA1

2.Sickle cell sample

3.Total fluorescence (no sample) value=818.80

-15-

TABLE 2

Sample	Meas. (F)	ΔF	Corning
1	700.2	95.1	5.3
1	697.6	97.7	5.3
2	705.4	89.9	5.7
2	697.6	97.7	5.7
3	673.4	121.9	6.0
3	679.6	115.7	6.0
4	669.1	126.2	6.6
4	670.6	124.7	6.6
5	638.0	157.3	7.6
5	639.0	156.3	7.6
6	656.4	138.9	7.9
6	660.2	135.1	7.9
7	657.3	138.0	8.1
7	667.5	127.8	8.1
8	646.7	148.6	8.3
8	638.0	157.3	8.3
9	638.0	157.3	8.4
9	645.9	149.4	8.4
10	609.7	185.6	8.8
10	604.5	190.8	8.8
11	608.5	186.8	9.1
11	605.3	190.0	9.1
12	619.7	175.6	9.4
12	618.1	177.2	9.4
13	638.6	156.7	9.6
13	643.0	152.3	9.6
14	613.9	181.4	10.5
14	622.0	173.3	10.5
15	620.7	174.6	10.7
15	629.3	166.0	10.7
16	543.3	252.0	11.4
16	551.1	244.2	11.4
17	588.4	206.9	11.5
17	593.7	201.6	11.5
18	585.1	210.2	12.3
18	587.2	208.1	12.3
19	602.4	192.9	13.3
19	603.6	191.7	13.3
20	572.8	222.5	13.6
20	571.3.	224.0.	13.6.

Total fluorescence (no sample) value=795.30

-16-

TABLE 3

	SAMPLE	%HbA1cc	FLUORESCENCE INDEX	ΔF
5	1	5.1	592.8	157.2
	2	6.2	598.8	151.2
	3	7.1	567.2	182.8
	4	8.0	575.1	174.9
	5	8.6	566.6	183.4
	6	9.0	569.6	180.4
10	7	10.1	572.7	177.3
	8	10.8	557.9	192.1
	9	11.2	548.0	202.0
	10	11.7	554.4	195.6
15	TOTAL FLUORESCENCE = 750			

TABLE 4

	SAMPLE	%HbA1cc	FLUORESCENCE INDEX	ΔF
20	1	5.1	560	90
	2	6.2	548	102
	3	7.1	514	136
25	4	8.0	525	125
	5	8.6	496	154
	6	9.0	502	148
	7	10.1	518	132
30	8	10.8	499	151
	9	11.7	510	140

TOTAL FLUORESCENCE = 650

-17-

TABLE 5

	SAMPLE	(approx) %HbA1c	FLUORESCENCE
			QUENCHING INDEX (ΔF)
5	High	13	61
	Medium	7	53
	Low	<1	42

10


-18-

CLAIMS


- 5 1. A method of carrying out an assay for a glycosylated protein in
a sample, which method comprises
carrying out a reaction in solution between an assay
sample and photoluminescent or chemiluminescent marker compound
containing a boronic acid group capable of selective binding
10 with the cis-diol group of a glycosylated protein, which marker
compound is not albumin-specific,
exciting the luminescence in the marker compound, and
detecting the resulting luminescence,
wherein the nature of the marker and the nature of the
15 excitation are such that the said luminescence occurs at a
wavelength at which it is preferentially quenched by the
binding of the said marker compound to the said glycosylated
protein, and
determining the quenching in luminescence due to the
20 binding of the said marker compound to the glycosylated protein.
2. A method as claimed in Claim 1, wherein the glycosylated
protein is glycosylated haemoglobin, or a plasma-soluble glycosylated
protein.
- 25 3. A method as claimed in Claim 1 or Claim 2, wherein the
sample is a blood sample, a plasma sample or a serum sample.
4. A method as claimed in any one of the preceding Claims,
30 wherein the photoluminescent compound is a fluorescent
compound.
5. A method as claimed in Claim 4, wherein the fluorescent
compound has a principal excitation wavelength of at least 450
35 nm.

-19-


6. A method as claimed in Claim 5, wherein the fluorescent compound has a principal excitation wavelength of from 450 to 800 nm.
- 5 7. A method as claimed in any one of Claims 4 to 6, wherein the fluorescent compound has a principal luminescence wavelength of from 450 to 600 nm.
8. A method as claimed in Claim 7, wherein the said principal
10 luminescence wavelength is approximately 520nm.
9. A method as claimed in any one of Claims 4 to 8, wherein the fluorescent compound contains a fluorescein residue.
- 15 10. A method as claimed in Claim 9, wherein the fluorescent compound is a group of the formula $F-NH-CS-NH-Ph-B(OH)_2$, wherein Ph is a phenyl group and F is a fluorescein residue.
11. A method as claimed in Claim 9, wherein the fluorescent
20 compound is a compound of the formula:-



1/5




2/5




3/5

Figure 3




4/5



5/5

Figure 5



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/01766

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/68 G01N33/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,90 13818 (HOLMES MICHAEL JOHN ;AXIS RESEARCH (NO)) 15 November 1990 cited in the application see page 9, line 29 - page 11, line 16 see page 12, line 16 - page 35; figure 3; example 2 ---	1-11
X	US,A,4 861 728 (WAGNER DANIEL B) 29 August 1989 cited in the application see column 4, line 19 - line 37 ---	1-11
X	DE,A,37 20 736 (SCHLEICHER ERWIN DR) 5 January 1989 cited in the application see claims; example 9 ---	1-11
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

20 November 1995

Date of mailing of the international search report

01.12.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Cartagena y Abella,P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/01766

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CLINICA CHIMICA ACTA, vol. 149, no. 1, 1985 pages 13-19, Y. HAYASHI ET AL. 'Fluorometric measurement of glycosylated albumin in human serum' cited in the application see the whole document ---	1-9
A	WO,A,93 18407 (ABBOTT LAB) 16 September 1993 cited in the application ---	
A	OPHTHALMIC RESEARCH, vol. 14, no. 6, 1982 pages 416-427, J. H. ROCKEY ET AL. 'Binding of fluorescein and carboxyfluorescein by normal and glycosylated human serum proteins.' -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 95/01766

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9013818	15-11-90	AT-T- 117806	15-02-95
		AU-B- 642879	04-11-93
		AU-B- 5667090	29-11-90
		CA-A- 2055430	12-11-90
		DE-D- 69016423	09-03-95
		DE-T- 69016423	14-06-95
		EP-A- 0471774	26-02-92
		ES-T- 2067029	16-03-95
		HU-A- 66835	30-01-95
		US-A- 5242842	07-09-93

US-A-4861728	29-08-89	NONE	

DE-A-3720736	05-01-89	NONE	

WO-A-9318407	16-09-93	CA-A- 2102417	05-09-93
		EP-A- 0589001	30-03-94
		JP-T- 6507978	08-09-94
